YU47802A - Methods and compositions for levovirin - Google Patents

Methods and compositions for levovirin

Info

Publication number
YU47802A
YU47802A YU47802A YUP47802A YU47802A YU 47802 A YU47802 A YU 47802A YU 47802 A YU47802 A YU 47802A YU P47802 A YUP47802 A YU P47802A YU 47802 A YU47802 A YU 47802A
Authority
YU
Yugoslavia
Prior art keywords
compound
compounds
levovirin
compositions
methods
Prior art date
Application number
YU47802A
Other languages
Serbo-Croatian (sh)
Inventor
Johnson Lau
Zhi Hong
Robert Tam
Kanda Ramasamy
Chin-Chung Lin
Fusun Zeytin
Ljubiša Rakić
Original Assignee
Ribapharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm filed Critical Ribapharm
Publication of YU47802A publication Critical patent/YU47802A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)

Abstract

Nucleoside and nucleotide compounds and their analogs/prodrugs are provided. Particularly contemplated compounds include 1-β-L-ribofuranosyl-1,2,4-triazole-3-carboxamide, which may be modified and/or phosphorylated. Contemplated compounds may further be combined with other pharmacological compounds, especially including Ribavirin, antibodies, and cytokines. Preferred uses of contemplated compounds include use as an antiviral compound, anti-inflammatory compound, antineoplastic compound, and as a compound to stimulate cellular growth.
YU47802A 1999-12-23 2000-12-19 Methods and compositions for levovirin YU47802A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US17209799P 1999-12-23 1999-12-23
US17344699P 1999-12-29 1999-12-29
US17511100P 2000-01-06 2000-01-06
US19075800P 2000-03-20 2000-03-20
US22694700P 2000-08-22 2000-08-22
US22687500P 2000-08-22 2000-08-22
US23354800P 2000-09-19 2000-09-19
US23382300P 2000-09-19 2000-09-19
US23382100P 2000-09-19 2000-09-19
US23382200P 2000-09-19 2000-09-19
US23546500P 2000-09-26 2000-09-26

Publications (1)

Publication Number Publication Date
YU47802A true YU47802A (en) 2006-03-03

Family

ID=27582702

Family Applications (1)

Application Number Title Priority Date Filing Date
YU47802A YU47802A (en) 1999-12-23 2000-12-19 Methods and compositions for levovirin

Country Status (20)

Country Link
EP (1) EP1244356A4 (en)
JP (1) JP2003523957A (en)
KR (1) KR20030032908A (en)
CN (1) CN1420723A (en)
AU (1) AU2442201A (en)
BR (1) BR0016162A (en)
CA (1) CA2384326A1 (en)
CZ (1) CZ20022112A3 (en)
HK (1) HK1049944A1 (en)
HR (1) HRP20020485A2 (en)
HU (1) HUP0300219A3 (en)
IL (1) IL148514A0 (en)
MX (1) MXPA02006251A (en)
NO (1) NO20022969L (en)
NZ (1) NZ517634A (en)
PL (1) PL364927A1 (en)
SI (1) SI20976A (en)
SK (1) SK8612002A3 (en)
WO (1) WO2001045509A1 (en)
YU (1) YU47802A (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
CA2537878A1 (en) 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Polymorphic nucleoside compounds
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
KR20090094800A (en) * 2006-09-11 2009-09-08 써던 리서취 인스티튜트 Azole nucleosides and use as inhibitors of rna and dna varial polymerases
CN102952104A (en) * 2011-08-17 2013-03-06 黑龙江省松花江药业有限公司 Furan compound
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN104387431A (en) * 2014-10-24 2015-03-04 江南大学 Preparation method of high-specificity ribavirin artificial antigens
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
RU2020126177A (en) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. ACETAL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS
CN109528638B (en) * 2018-12-20 2021-07-06 江西润泽药业有限公司 Ribavirin derivative preparation and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
EP0262125B1 (en) * 1986-03-27 1996-03-27 Gensia, Inc. AICA riboside for the prophylactic treatment of diseases with restricted blood flow.
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
PT1027359E (en) * 1996-10-16 2003-09-30 Ribapharm Inc ANALOG MONOCYCLIC L-NUCLEOSIDEOS AND ITS UTILIZATIONS
ES2172288T3 (en) * 1998-05-15 2002-09-16 Schering Corp COMBINATION THERAPY THAT UNDERSTANDS RIBAVIRINA AND INTERFERED ALPHA IN PATIENTS WHO HAVE NOT BEEN SUBJECTED TO ANTIVIRAL TREATMENT AND HAVE CHRONIC HEPATITIS C INFECTION.
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
WO2000030656A1 (en) * 1998-11-20 2000-06-02 The Salk Institute For Biological Studies Neuron stimulation by ribavirin, and analogs thereof

Also Published As

Publication number Publication date
HUP0300219A2 (en) 2003-06-28
MXPA02006251A (en) 2003-01-28
NO20022969D0 (en) 2002-06-20
NO20022969L (en) 2002-06-20
BR0016162A (en) 2002-08-13
CN1420723A (en) 2003-05-28
SK8612002A3 (en) 2003-03-04
HUP0300219A3 (en) 2005-07-28
NZ517634A (en) 2004-06-25
WO2001045509A1 (en) 2001-06-28
AU2442201A (en) 2001-07-03
CZ20022112A3 (en) 2003-05-14
SI20976A (en) 2003-02-28
CA2384326A1 (en) 2001-06-28
PL364927A1 (en) 2004-12-27
HRP20020485A2 (en) 2005-10-31
KR20030032908A (en) 2003-04-26
JP2003523957A (en) 2003-08-12
EP1244356A1 (en) 2002-10-02
IL148514A0 (en) 2002-09-12
EP1244356A4 (en) 2003-03-19
HK1049944A1 (en) 2003-06-06

Similar Documents

Publication Publication Date Title
WO2002100354A8 (en) Pyrrolo[2,3-d]pyrimidine nucleoside analogs
YU47802A (en) Methods and compositions for levovirin
MXPA02012156A (en) Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides.
MXPA04001361A (en) Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue.
DE60101223D1 (en) ANTIVIRAL PYRIMIDINE NUCLEOSIDE DERIVATIVES
AU4039097A (en) Propargylethoxyamino nucleotides
AU674639B2 (en) 3'-substituted nucleoside derivatives
NO20020931L (en) Pyrrolo [2,3-d] pyrimidine nucleoside analogs
MY150408A (en) P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-ß-D-RIBOFURANOSYL)-3H-THIAZOLE[4,5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION
WO2000053167A3 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
IL150061A0 (en) Purine derivatives
DE69839781D1 (en) Heterocyclische topoisomerase toxine
DE602004031115D1 (en) PYRIMIDINE COMPOUNDS WITH PHOSPHONATE GROUPS AS AN ANTIVIRAL NUCLEOTIDE ANALOG
WO2000061594A3 (en) Nucleoside derivatives with photo-unstable protective groups
HK1078781A1 (en) Processes for preparing 1,3-dioxolane nucleosides
JPS6426593A (en) Nucleoside derivative
GB9506644D0 (en) Preparation of nucleoside analogues
JO2402B1 (en) Process for producing a ribofuranose
PL360582A1 (en) Purine ribosides as antiarrhythmics
WO2008026222A3 (en) Process and intermediates of 2,2' difluoronucleosides
JPS56142298A (en) Oligonucleotide derivative and its preparation